Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07288879 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DALY II Japan/MB-CART2019.1 for DLBCL

Study acronym: DALY II Japan
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 10, 2025 to Dec 11, 2025 · Study sites revised (5)v3 Show 2 more changesShow less
    • Start date changed from estimate of Dec 10, 2025 to Dec 11, 2025
    • Study sites revised (5)

    See this version in full on ClinicalTrials.gov ↗

  2. Secondary endpoints revised (13)v2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.
Trial Details
NCT Number NCT07288879
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov